Drugs in MeSH Category Anesthetics, Dissociative

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gland	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	216809-002	Jan 24, 2023	AP	RX	No	No
Eugia Pharma	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	076092-001	Sep 30, 2008	AP	RX	No	No
Eugia Pharma	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	076092-002	Dec 28, 2001	AP	RX	No	No

Market Dynamics and Patent Landscape for NLM MeSH Class: Anesthetics, Dissociative

Last updated: July 16, 2026

Dissociative anesthetics (MeSH: “Anesthetics, Dissociative”) are dominated commercially by ketamine products, with patent and exclusivity risk concentrated in ketamine formulations (oral/sublingual/extended-release where applicable), stereo- and enantiomer-specific assets (where pursued), and method-of-use or procedural protocol patents around procedural sedation. Key market dynamics are driven by (i) generic entry pressure once formulation and use patents expire, (ii) FDA control of REMS and distribution constraints for certain products, and (iii) payer and site-of-care substitution toward lower-cost generics when dosing, onset profile, and tolerability claims are not protected.

This analysis maps the patent estate and market drivers by “drug family,” then lists the highest-probability exclusivity and patent barriers that affect generic and competitor entry.

---

What dissociative anesthetics are driving the market in MeSH “Anesthetics, Dissociative”?

Answer: Ketamine-based products are the core revenue and volume drivers. Competition risk typically comes from approved generic ketamine hydrochloride solutions and from formulation competitors where brand manufacturers carved out exclusivity for specific presentations or dosing regimens.

Which actives are typically included under “Anesthetics, Dissociative”

Across FDA/clinical practice, the dissociative anesthetic class is anchored by:

• Ketamine (racemic): intravenous and intramuscular anesthesia/sedation; also oral formulations for specific indications where approved.
• Esketamine: intranasal for treatment-resistant depression (this is mechanistically dissociative but is often categorized outside anesthetic-only market segments in commercial datasets).

Because MeSH “Anesthetics, Dissociative” is classification-based, the patent landscape is broader than “ORAL anesthetics” and includes psychiatric use where the same dissociative mechanism patents can overlap.

---

How do patent estates differ between ketamine, esketamine, and other dissociative anesthetics?

Answer: Ketamine’s patent risk is usually formulation and method-of-use focused, while esketamine tends to have a more concentrated brand estate around delivery system, specific indication, and label-linked method-of-use claims.

Ketamine: why patents cluster around formulation and use

Generic ketamine hydrochloride injection faces the practical issue that the active is old, and composition-of-matter coverage for ketamine is historical. The actionable “barriers” usually come from:

• sterile formulation specifics (pH, excipients, stability and container-closure)
• procedural sedation protocols (method-of-use)
• dosing regimen claims tied to labeled or studied administration paradigms

Esketamine: why patents are more delivery and label linked

For esketamine intranasal, the protected subject matter typically includes:

• nasal delivery technology and formulation constraints
• manufacturing and device integration
• label-linked endpoints and method-of-use claims in the depression population

---

When do dissociative anesthetic patents and exclusivity expire, and what triggers generic entry?

Answer: For most “classic” ketamine injection products, exclusivity has largely passed; remaining barriers are individual, late-cycle patents on specific presentations and indications. Entry timing is governed by the last expiring patent in the relevant Orange Book listing for the exact NDA/NDC and by any patent-scope affecting generic filers.

Generic entry triggers that matter most

1. Orange Book last listed patent expiry for the brand’s exact drug product/NDC.
2. Patent expiration vs. regulatory exclusivity:
   • 505(b)(2) exclusivity blocks certain pathways even when patent coverage is thin.
   • pediatric exclusivity and orphan exclusivity can extend periods even with narrow patent coverage.
3. Hatch-Waxman litigation and settlements:
   • if Paragraph IV challenges lead to a district court stay or settlement that caps launch.
4. REMS and distribution rules:
   • does not replace IP, but can reduce the pace of market substitution for certain products.

Practical “timing map” for investor planning

• High likelihood of generic availability: ketamine hydrochloride injection where late patents are not tied to the same NDC presentation.
• Slower substitution: branded or unique delivery systems (for example, intranasal esketamine) where formulation and device-related patents are more persistent.
• Outcomes differ by jurisdiction: US Orange Book drives US generics; EU and UK rely on SPCs and national validation of counterpart families.

---

What patents protect ketamine and esketamine formulations under the Orange Book?

Answer: The Orange Book typically lists patents for:

• drug substance (older and often expired),
• drug product (formulation and composition),
• methods of use (tied to labeled indications and study-defined regimens),
• and sometimes manufacturing (process controls that are hard for challengers to design around).

How to interpret Orange Book listings for dissociative anesthetics

For market-risk screening, use this rule set:

• If the last listed patents are method-of-use, a generic can often use the same active and file a narrower label, but launch may still be blocked if the generic’s proposed use infringes.
• If the last listed patents are formulation/manufacturing, design-around is possible but costly, often leading to slower entry or licensing.
• If the last listed patents are tied to a specific delivery device or integrated nasal system, entry risk rises because the generic must match delivery performance claims.

---

How many patents cover dissociative anesthetic brands, and which assignees control the estate?

Answer: In practice, most dissociative anesthetic estates are controlled by:

• originator brand holders for the key NDA (often with multiple continuation families),
• and later formulation assignees for specific presentations (especially if product line expansions were spun into new NDA supplements or 505(b)(2).

Typical estate structure

• Early core families: ketamine or esketamine chemistry (often expired)
• Mid-cycle: delivery system and formulation patents (frequently the “last listed”)
• Late-cycle: polymorph/particle size where relevant, container-closure stability, and method-of-use refinements tied to label expansions

Assignee control is often split by time because supplements and new delivery tech are commonly developed by different R&D units or acquired.

---

Which Paragraph IV challenges are most likely for dissociative anesthetics?

Answer: Paragraph IV risk is highest where (i) a branded formulation has remaining Orange Book coverage, and (ii) the generic filer can plausibly argue non-infringement or invalidity without redesigning key product attributes.

Typical Paragraph IV focal points

• drug product patents: excipient and stability system
• method-of-use: route-specific or indication-specific treatment regimens
• manufacturing patents: process steps tied to performance and impurity profiles

Settlement dynamics to watch

If a Paragraph IV action occurs, market access is usually shaped by:

• a “carve-out” settlement allowing earlier supply for non-overlapping NDCs
• a delay-and-pay arrangement that sets a launch date aligned to the last patent expiry
• a stipulation on label limitations to avoid infringement

---

What patent litigation affects ketamine and esketamine generic and biosimilar competition?

Answer: The actionable litigation for dissociative anesthetics is generally patent-centered rather than biologics-focused (biosimilars are not the dominant competitive lane because these are small molecules). Risk events include district court rulings affecting claim scope and injunction reach, and settlements that define the generic’s permissible label.

What to expect in litigation outcomes

• Claim construction can narrow method-of-use or formulation claims into non-overlapping differences.
• Generic invalidity arguments often target obviousness combinations (process/formulation known in the art) and lack of inventive step.
• Design-around efforts can shift infringement analysis from composition to process.

---

Are biosimilar risks relevant for dissociative anesthetics?

Answer: Biosimilar risks are generally low because the key dissociative anesthetics (ketamine, esketamine) are small molecules without biologics manufacturing and no biosimilar pathway. Competition instead follows generic ANDA and, for some presentations, 505(b)(2) hybrid pathways.

---

What formulations are protected by patents for dissociative anesthetics?

Answer: Protected formulations are usually presentation-specific: injection composition and stability system for ketamine, and nasal formulation/delivery integration for esketamine.

Formulation and delivery categories that create patent barriers

• Sterile injectable solutions: pH targets, solubilizers, stability under temperature excursions, and container-closure pairing
• Intranasal systems: sprayed formulation viscosity, particle size/atomization profile, device integration and dosing consistency
• Oral formulations (where approved): dissolution profile and release timing, coating/excipient selection, and impurity control targets

---

How strong is the patent estate for dissociative anesthetic brands?

Answer: Strength tends to be moderate for “brand-injection” ketamine products when late-stage Orange Book listings are method-of-use or narrow formulation claims. Strength tends to be higher for delivery-system brands where the last listed patents are drug product patents with clear performance-linked characteristics.

Strength drivers that matter for business planning

• Remaining term to last listed patent expiry in the target NDC
• Claim dependency: whether infringement hinges on a specific excipient, concentration range, or device parameter
• Litigation history: repeated continuation filings often correlate with broader continuation defense strategies
• Commercial necessity: if the branded product’s differentiated label requires the patented feature, design-around is more expensive

---

How does ketamine compare with esketamine in patent risk and market substitution?

Answer: Ketamine injection is more substitution-ready once NDC-specific formulation patents expire. Esketamine intranasal faces slower substitution due to tighter delivery and indication linkages in its patent estate and label.

Competitive substitution map

Attribute	Ketamine (typical injection segment)	Esketamine (intranasal)
Main IP barrier	presentation-specific formulation/method-of-use	delivery system + drug product + label-linked use
Generic entry readiness	higher after last formulation/method-of-use expiry	lower; design-around is harder
Market dynamics	price competition once barriers lift	brand differentiation persists longer

---

What is the Orange Book status of key dissociative anesthetic drugs?

Answer: Orange Book status is NDC- and presentation-specific. For market planning, you screen by the exact brand product that matches the dosage form and route used in institutional purchasing.

How to use Orange Book status operationally

• Identify the last listed patent(s) for each branded NDC.
• Map which patents are type drug product vs method of use.
• Align the planned ANDA/505(b)(2) route:
  • If the applicant’s proposed label overlaps the method-of-use patent, expect infringement risk unless the design avoids the claim elements.
  • If the patents are drug product oriented, the generic needs product parity or a clear separation.

---

Commercial and regulatory constraints that shape real-world entry for dissociative anesthetics

Answer: Regulatory requirements (FDA labeling, distribution controls, and any REMS where applicable) can constrain substitution pace even after IP expiry. Payer contracting and hospital formulary committees decide speed.

Site-of-care dynamics

• Hospital purchasing often bundles anesthesia/sedation supply contracts where price is decisive once IP is cleared.
• Emergency and procedural sedation protocols favor dosing reliability and clinician familiarity, which may delay adoption of a generic if clinical equivalence is not operationally seamless.

Distribution and controlled handling

• Ketamine is typically subject to controlled substance requirements; brand distributors and institutional buyers have entrenched supply chains. This can slow vendor switching even when generics are legally available.

---

Where are the biggest patent/IP barriers to generic launch for dissociative anesthetics?

Answer: The biggest barriers are typically not the old ketamine molecule. They are:

• last-cycle formulation/drug product patents on the specific NDC/dosage form,
• late method-of-use patents that map to labeled procedural sedation or psychiatric indication regimens,
• and litigation/settlement terms that delay launch beyond theoretical patent expiry.

Common “barrier patterns” by claim type

• Drug product: excipient and stability constraints that are hard to replicate without performance equivalence.
• Method-of-use: label-aligned dosing timing or clinical criteria that are difficult for generics to avoid without label narrowing.
• Manufacturing: process-specific steps tied to impurity profiles that regulators scrutinize in quality reviews.

---

Key Takeaways

• The dissociative anesthetic market is dominated by ketamine and, depending on segment definitions, esketamine. Competitive pressure hinges on presentation-specific patents, not the underlying old small molecule chemistry.
• The most consequential “barriers” are Orange Book last listed drug product and method-of-use patents tied to exact NDCs and labeled regimens.
• Generic entry timing is driven by last patent expiry, regulatory exclusivity, and Paragraph IV litigation/settlement terms that define launch dates and permissible labels.
• Biosimilar risk is low because these are small molecules; competition is mainly ANDA/505(b)(2).
• Real-world substitution is also shaped by site-of-care contracting, controlled handling logistics, and label-linked adoption behavior.

---

FAQs

1. What claim types most often remain in-force for dissociative anesthetic brands near patent expiry?
2. How do method-of-use patents for procedural sedation affect ANDA label design for ketamine products?
3. What settlement provisions commonly delay generic launch for dissociative anesthetics even after patent expiration?
4. Which formulation attributes are usually scrutinized for equivalence in nasal esketamine generic or 505(b)(2) products?
5. How do NDC-level Orange Book listings change market-entry strategy for hospitals sourcing dissociative anesthetics?

---

References (APA)

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
2. National Library of Medicine. “MeSH: Anesthetics, Dissociative.” U.S. National Library of Medicine.
3. FDA. “Hatch-Waxman Act: Patent and Exclusivity.” U.S. Food and Drug Administration.